Table 2:
Overall survival stratified by progression status at week 16
| Sequence | Progression by Week 16? |
Progression by Week 16? (R vs NR-NP) |
|||
|---|---|---|---|---|---|
| No |
Yes |
R |
NR-NP |
P |
|
| N (%), Median OS (days) (95% CI) | N (%), Median OS (days) (95% CI) | N (%), Median OS (days) (95% CI) | N (%), Median OS (days) (95% CI) | N (%), Median OS (days) (95% CI) | |
| 2D | 36 (63%) | 21 (37%) | 16 (28%) | 20 (35%) | 21 (37%) |
| 448 (321–660) | 212 (170–268) | 437 (319–971) | 451 (232–687) | 212 (170–268) | |
| P < .0001a (n = 57) | P = .73: R vs NR-NP | ||||
| dT1 | 31 (54%) | 26 (46%) | 23 (40%) | 8 (14%) | 26 (46%) |
| 434 (319–676) | 221.5 (196–309) | 448 (319–687) | 362.5 (127, –) | 221.5 (196–309) | |
| P = .006a (n = 57) | P = .61: R vs NR-NP | ||||
Note:— – indicates those that were still alive at the end of study (i.e., no upper bound); N, number of patients; R, responder; NR-NP, non-responder/non-progressor; P, progressor.
a
Significant.